Dry Powder Inhaler Containing Treprostinil Gets FDA Approval
Tyvaso DPI is a drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler.
Tyvaso DPI is a drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler.
Evinacumab is a fully-human monoclonal antibody that binds to and blocks the function of angiopoietin-like 3
Tamara Horwich, MD, Eugenia Gianos, MD, and Kenneth Fleisher, DDS, reflect on the link between cardiovascular disease and oral health.
Investigators examined the effect of obesity on microvascular and macrovascular complications among patients with type 1 or type 2 diabetes.
While food insecurity is a leading public health issue, research shows that nutrition security may be a better target for disease prevention strategies.
Researchers sought to evaluate whether there is any evidence from real-world data on treatment with tofacitinib, tocilizumab, or tumor necrosis factor and the risk for ADRD.
Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin.
A study was conducted to determine the relationship between breast arterial calcification and risk for atherosclerotic cardiovascular disease.
The authors searched 4 international databases for studies reporting on myopericarditis in temporal relation to vaccination in the general population.
Investigators sought to determine if an association existed between weight change and major cardiovascular outcomes among patients with type 2 diabetes.